Five Below Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Five Below Inc trades at $234.75 (market cap $12.95B), while State Street SPDR S&P Biotech ETF trades at $159.3. Which is the better fit depends on your goals.
| FIVE | XBI | |
|---|---|---|
Market Cap | $12.95B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $247.71 | $164.28 |
52-Week Low | $134.36 | $86.92 |
Enterprise Value | $13.84B | — |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $235.36, down 3.69% on the day but maintains strong technical momentum with bullish moving averages. The company demonstrates consistent revenue growth, reaching $3.88B in 2025, and has beaten earnings estimates in three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $256.45 consensus price target, representing 9% upside potential from current levels.
FIVE presents a compelling growth story with expanding store footprint and product innovation driving sales. Key risks include consumer spending sensitivity and competitive retail pressures. The stock's premium valuation (P/E 29.53) requires continued execution, but strong institutional interest and positive earnings momentum support the bullish case for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →